Study guide
12.2 Neonatal Hyperbilirubinemia & Hematologic Complications
RNC-MNN Maternal Newborn Nursing Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 RNC-MNN Credential Overview, Eligibility & Exam Format 1.2 Evidence-Based Nursing Practice, Legal-Ethical Standards & Study Strategies
2 Chapter 1: Pregnancy & Intrapartum Risk Factors
2.1 Pre-existing Maternal Conditions, Gestational Complications & High-Risk Antepartum Factors 2.2 Intrapartum Complications: Labor Abnormalities, Rupture of Membranes & Chorioamnionitis 2.3 Operative Delivery, Anesthesia Effects & Perinatal Trauma
3 Chapter 2: Maternal Postpartum Physical Assessment & Recovery
3.1 Uterine Involution, Fundal Assessment & Lochial Progression 3.2 Perineal Healing, Episiotomy, Lacerations & Cesarean Wound Evaluation 3.3 Cardiopulmonary, Renal, Gastrointestinal & Musculoskeletal Adaptations
4 Chapter 3: Maternal Nursing Care, Psychosocial Health & Education
4.1 Multimodal Pain Management, Early Ambulation & Bladder/Bowel Recovery 4.2 Psychosocial Transition: Rubin's Phases, Family Bonding & Perinatal Mood Screening 4.3 Patient Education, Contraception, Immunizations & POST-BIRTH Warning Signs
5 Chapter 4: Lactation & Infant Feeding
5.1 Breast Anatomy, Lactogenesis & Endocrine Regulation 5.2 Latch Mechanics, Milk Transfer Assessment (LATCH Score) & Feeding Frequency 5.3 Nipple Trauma, Engorgement, Ankyloglossia & Safe Formula Feeding
6 Chapter 5: Normal Newborn Transition & Assessment
6.1 Cardiopulmonary Transition, Thermal Balance & Cold Stress Prevention 6.2 Systematic Head-to-Toe Examination & Normal Physiologic Variations 6.3 Gestational Age Assessment (New Ballard Score) & Primitive Reflexes
7 Chapter 6: Routine Newborn Care, Resuscitation & Screening
7.1 Immediate Post-Birth Care, Vitamin K, Eye Prophylaxis & Umbilical Cord Care 7.2 Universal Screenings: CCHD, Universal Hearing Screen & Metabolic Bloodspots 7.3 Neonatal Resuscitation Program (NRP) 9th Edition Core Algorithm 7.4 AAP Safe Sleep Guidelines, SUID Prevention & Parent Guidance
8 Chapter 7: Postpartum Hemorrhage & Hematologic Disorders
8.1 Postpartum Hemorrhage: Definitions, Risk Factors & The 4 Ts 8.2 Quantitative Blood Loss (QBL), PPH Staging & Pharmacologic/Surgical Protocols 8.3 Postpartum Coagulopathies (DIC, ITP) & Venous Thromboembolism (DVT, PE)
9 Chapter 8: Postpartum Infections, Hypertension & Cardiopulmonary Emergencies
9.1 Preeclampsia, Eclampsia & HELLP Syndrome in the Postpartum Period 9.2 Endometritis, Surgical Site Infections, UTI & Mastitis 9.3 Maternal Sepsis: Recognition, Resuscitation & Source Control 9.4 Postpartum Cardiopulmonary & Neurologic Emergencies
10 Chapter 9: Endocrine, Psychiatric & Substance Use Complications
10.1 Gestational & Pre-existing Diabetes Postpartum & Postpartum Thyroiditis 10.2 Postpartum Depression, Anxiety Disorders & Postpartum Psychosis 10.3 Perinatal Substance Use, Opioid Use Disorder, Withdrawal & Harm Reduction
11 Chapter 10: Newborn Respiratory & Cardiovascular Complications
11.1 Transient Tachypnea (TTN), Respiratory Distress Syndrome (RDS) & Meconium Aspiration (MAS) 11.2 Congenital Heart Defects (Cyanotic vs. Acyanotic) & Postpartum Presentation 11.3 Persistent Pulmonary Hypertension of the Newborn (PPHN) & Apnea/Bradycardia
12 Chapter 11: Newborn Metabolic, Neurologic, Gastrointestinal & Infectious Complications
12.1 Neonatal Glucose, Electrolyte, Endocrine & Metabolic Disorders 12.2 Neonatal Hyperbilirubinemia & Hematologic Complications 12.3 Early-Onset & Late-Onset Neonatal Sepsis, GBS & TORCH Infections 12.4 Neonatal Abstinence Syndrome (NAS/NOWS) & Birth Trauma/Injuries 12.5 Neonatal Neurologic & Gastrointestinal Complications
12.2 Neonatal Hyperbilirubinemia & Hematologic Complications
Key Takeaways Explain This Topic AI
Measure bilirubin at least once before discharge; jaundice in the first 24 hours requires prompt objective measurement and evaluation.
Use hour-specific AAP phototherapy and exchange thresholds based on gestational age and neurotoxicity risk factors—not the retired Bhutani risk-zone nomogram.
A bilirubin rise of at least 0.3 mg/dL/hour in the first 24 hours or 0.2 mg/dL/hour thereafter suggests hemolysis and warrants evaluation.
Plan follow-up by the difference between measured bilirubin and the applicable phototherapy threshold, together with age, feeding, weight, and support.
Pallor, plethora, petechiae, bleeding, poor perfusion, or neurologic/feeding change may signal anemia, polycythemia, thrombocytopenia, or VKDB and needs cause-directed evaluation.
Last updated: September 2026
12.2 Neonatal Hyperbilirubinemia & Hematologic Complications
Core Focus: Bilirubin care is threshold-based and individualized. Hematologic disorders can produce jaundice, bleeding, thrombosis, hypoxia, or shock, so assess the infant rather than treating color alone.
Bilirubin surveillance
Visually assess jaundice regularly, but estimate neither level nor treatment need from skin color alone. Obtain a transcutaneous or serum bilirubin at least once between 24 and 48 hours or before an earlier discharge. Jaundice during the first 24 hours requires prompt TcB/TSB measurement and evaluation.
Obtain a confirmatory TSB when TcB is within 3 mg/dL of the phototherapy threshold or TcB is at least 15 mg/dL. Treatment decisions use TSB. Plot the value by age in hours, gestational age, and hyperbilirubinemia neurotoxicity risk factors on the current AAP phototherapy and exchange-transfusion curves. Do not use the retired Bhutani “low/intermediate/high-risk zone” nomogram to decide treatment or follow-up.
A rise >=0.3 mg/dL/hour in the first 24 hours or >=0.2 mg/dL/hour thereafter suggests hemolysis. Evaluate blood type/DAT when indicated, CBC/hematocrit, reticulocytes and smear, G6PD testing when risk or unexplained course warrants, feeding, weight, stool/urine, bruising/hematoma, infection, and family history.
Patterns and causes
Physiologic bilirubin production rises after 24 hours because newborn red-cell turnover is high and hepatic conjugation is immature. Suboptimal-intake hyperbilirubinemia occurs in the first week with ineffective transfer, excess weight loss, low output, and delayed stooling; correct feeding and supplement when medically indicated. Human-milk jaundice can persist in a thriving infant after adequate intake is established, but other causes must be excluded.
ABO or Rh isoimmune hemolysis, G6PD deficiency, hereditary spherocytosis, sepsis, cephalohematoma/subgaleal blood, and polycythemia increase bilirubin load. Direct/conjugated bilirubin above 1 mg/dL is abnormal and prompts cholestasis evaluation, especially with dark urine, pale stool, poor growth, or hepatomegaly. Phototherapy removes unconjugated bilirubin; a cholestatic infant may still need phototherapy for a dangerous unconjugated component, so “never phototherapy” is incorrect.
Treatment and follow-up
Intensive phototherapy uses blue-green light with irradiance and exposed surface area meeting device/protocol standards. Protect eyes, maintain thermoregulation, support feeding/hydration, monitor TSB and output, and avoid routine water or dextrose-water supplements. Escalation-of-care and exchange thresholds are lower when neurotoxicity risks are present. Signs of acute bilirubin encephalopathy—poor suck, lethargy/hypotonia progressing to hypertonia, retrocollis/opisthotonus, high-pitched cry, apnea, or seizure—are an emergency.
Before discharge, calculate how far the TSB is below the applicable phototherapy threshold. A smaller margin requires earlier follow-up. Include gestational age, feeding adequacy, weight trajectory, hemolysis risk, family support, and ability to obtain a bilirubin. Give explicit return precautions.
Anemia and hemolytic disease
Anemia may reflect blood loss, fetomaternal or twin-to-twin transfusion, occult hemorrhage, hemolysis, infection, or reduced production. Pallor, tachycardia, weak pulses, poor feeding, tachypnea, or shock requires CBC/reticulocyte assessment and source evaluation. Treat physiology and cause; transfusion decisions depend on symptoms, level, age, and disease context.
Isoimmune hemolytic disease can cause early jaundice and anemia. A positive DAT supports antibody coating but does not by itself predict severity. G6PD deficiency can cause severe, sometimes sudden hemolysis; avoid known oxidant exposures and arrange family education/testing under the care plan.
Polycythemia and hyperviscosity
Confirm a high capillary hematocrit with a venous sample; venous hematocrit >=65% defines neonatal polycythemia. Hyperviscosity can cause ruddy color, lethargy, poor feeding, hypoglycemia, respiratory distress, cyanosis, thrombosis, or neurologic findings. Management depends on symptoms and venous value; ensure appropriate hydration/glucose evaluation and follow neonatal orders rather than treating a capillary number alone.
Thrombocytopenia and VKDB
Platelets below 150,000/µL define thrombocytopenia, but bleeding risk and treatment depend on count, trend, gestational age, clinical illness, and cause. Early causes include placental insufficiency and maternal immune thrombocytopenia; severe illness/sepsis, NEC, congenital infection, alloimmune thrombocytopenia, and genetic disease are important differentials. Petechiae, mucosal bleeding, or neurologic change requires urgent evaluation; suspected neonatal alloimmune thrombocytopenia carries intracranial-hemorrhage risk.
Vitamin K deficiency bleeding can occur early with maternal drug effects, classically in the first week, or late—often 2 to 12 weeks—in infants who did not receive reliable prophylaxis, especially when exclusively human-milk fed or cholestatic. Bleeding from the cord/circumcision, GI bleeding, bruising, pallor, bulging fontanelle, seizure, or shock demands emergency coagulation studies and treatment. IM vitamin K after birth is the most reliable prevention.
Safe transitions across settings
Communicate the last bilirubin value, exact collection age, applicable treatment threshold, rate of rise, feeding plan, weight change, hemolysis results, phototherapy history, and scheduled follow-up to both family and receiving clinician. Home phototherapy is appropriate only for carefully selected infants who meet current criteria and have reliable equipment, daily bilirubin measurement, adequate feeding, and rapid access to care. Readmission is safer when neurotoxicity risk, rapid rise, illness, or unreliable follow-up is present.
After phototherapy, obtain rebound testing when the infant's age at treatment, hemolysis, gestational age, or treatment course creates meaningful risk. Teach that visual improvement does not prove the bilirubin is safe and that sunlight is not a controlled substitute for medical phototherapy.